Na Cocer Peptides bin rayt am 
1 mɔnt dɔn pas
ƆL DI ATIKUL ƐN PRODƆKT INFƆMƐSHƆN WE DƐN GI NA DIS WƐBSAYT NA FƆ ƆL FƆ DI INFƆMƐSHƆN ƐN FƆ EDYUKESHƆN.
Di prɔdak dɛn we dɛn gi na dis wɛbsayt na fɔ in vitro risach nɔmɔ. in vitro risach (Latin: *in glas*, we min insay glas) dεn de du am ausayd mכtalman bכdi. Dɛn prɔdak ya nɔto mɛrɛsin, dɛn nɔ gɛt di aprɔval frɔm di US Food and Drug Administration (FDA), ɛn dɛn nɔ fɔ yuz dɛn fɔ protɛkt, trit, ɔ mɛn ɛni mɛrɛsin, sik, ɔ sik. Di lɔ nɔ gri fɔ mek dɛn put dɛn tin ya insay mɔtalman ɔ animal bɔdi ɛni we.
1. Introdukshɔn
Fɔ fat dɔn bi wan tin we de mɔna pipul dɛn fɔ gɛt wɛlbɔdi ɔlsay na di wɔl, ɛn dis dɔn rili mek pipul dɛn gɛt difrɛn prɔblɛm dɛn lɛk sik dɛn we de ambɔg dɛn at ɛn shuga. Fɔ fɛn fayn fayn mɛrɛsin fɔ mɛn pɔsin we fat pasmak na sɔntin we rili impɔtant. Survodutide, as dual agonist we de akt pan di glukagon rεsεpכta (GCGR) εn di glukagon lεk pεptida-1 rεsεptכr (GLP-1R), de sho big pכtεnshal insay di fil fכ fכ trit fכ fat.
Figure 1 ifekt dεm we glukagon lεk pεptida-1 (GLP-1), glukכs-dipεndεnt insulinotropik polipεptida (GIP), εn glukagon gεt pan difrεn imכtant כgan dεm εn tisu dεm.
2. Ɔvaviu fɔ Survodutide
2.1 Divɛlɔpmɛnt Bakgrɔn
Di wɔl insidɛns fɔ fat ɛn tayp 2 dayabitis (T2DM) de kɔntinyu fɔ go ɔp, ɛn tradishɔnal antidiabetic drɔgs bɔku tɛm kin mek pɔsin gɛt mɔ wet, we kin mek dɛn nid nyu tritmɛnt kwik kwik wan we kin trit T2DM ɛn fat wan tɛm. GLP-1 rεsεptכr agonist dεm (GLP-1 RAs) εn dual GLP-1/GIP rεsεptכr agonist dεn dכn sho se dεn de wok fכ lכs wet εn mεtabolik improvεmεnt, Survodutide (BI 456906) dεn kכmכt as prכmis kandidet, wan lכng-aktin dual agonist dεm we dεn de invεstigat naw.
2.2 Di Mɛkanism fɔ Target
di yunik fכm we Survodutide gεt de insay in abiliti fכ aktibכt GCGR εn GLP-1R wan tεm. GCGR fכs de rεgεl di blכd glukכs lεvεl, we de protεkt glycogenolysis εn gluconeogenesis insay di liva we i aktibכt, we de εlevεt di bכdi glukכs lεvεl. insay di mεkanism fכ akshכn fכ Survodutide, i nכ de jכs rεs di blכd glukכs lεvεl bכt insted i de rεgεl εnεji mεtabolism tru sinagεstik akshכn wit GLP-1R. GLP-1R de sheb plεnti tisu dεm εn כgan dεm, inklud di pankrias, gεstrointestinal trakt, at, εn bren. we yu aktiv GLP-1R i de mek insulin sekreshכn, i de inhibit glukagon sekreshכn, i de delay di gεstrik εmpti, i de mek di satiety bכku, we de mek di it we yu de it rεdכks εn i de lכs di bכdi wet. Survodutide de εksyεrt wan mכr kכmprεhεnsiv mεtabolik rεgεdyushכn ifekt tru dual rεsεpכta agonism, we de εp fכ trit fכ fat.
3. Di Rol we Survodutide de ple pan Ɔbisiti Tritmɛnt
3.1 Weyt Rɛgyuleshɔn Ifɛkt
Bɔku klinik stɔdi dɛn dɔn sho se Survodutide gɛt impɔtant we fɔ ridyus di wet pan pipul dɛn we fat. Insay wan Faz 2 klinik trayal we dɛn tɔch fat pipul dɛn we nɔ gɛt dayabitis, 387 patisipan dɛn we ol 18 to 75 ia wit bɔdi mas indeks (BMI) ≥27 kg/m² bin randomly asaynd to fayv grup, we bin de gɛt ɛvri wik sabkyutan injɛkshɔn fɔ Survodutide (0.6, 2.4, 3.6, ɔ 4.8 mg) ɔ plasɛbo fɔ 46 wik. na di εnd כf 46 wik, כl di Survodutide doz grup dεm sho weit lכs, wit di 4.8 mg grup we achiv wan avrej weit rεdukshכn we rich 18.7%. Frɔm di sabgrup analisis bay jɛnɛral ɛn BMI, uman dɛn sho mɔ pronɔns weit lɔs afta dɛn dɔn gɛt 4.8 mg Survodutide, wit avrej wet lɔs pasɛnt we na -17.0%, we man dɛn gɛt -11.9%. Na difrεn BMI sabgrup dεm, patisipan dεm wit BMI < 30 kg/m² we bin gɛt Survodutide 4.8 mg tritmɛnt bin ɛkspiriɛns di ays wet lɔs pasɛnt, we rich -19.1%. Dis sho se Survodutide gɛt wet-ridyus ifɛkt pan fat pasɛnt dɛn we gɛt difrɛn jɛnɛral ɛn BMI lɛvɛl, wit mɔ pronɔns ifɛkt pan sɔm sabgrup dɛn.
Fig 2 Praymari Ɛnd Point afta 48 Wik we dɛn dɔn plan fɔ trit.
3.2 Efεkt dεm pan di bכdi fεt distribushכn
Apat frɔm di tɔtal wet lɔs, Survodutide bin gɛt bɛnifit ifɛkt bak pan bɔdi fat distribyushɔn. We yu kɔmpia am wit di plasɛbo grup, ɔl di Survodutide doz grup dɛn sho se di wɛst sɛkɔnfɛreshɔn dɔn ridyus, wit di 4.8 mg grup we ajɔst di big big avɛrej ridyushɔn we na 16.6 cm. we di wεst sεkshכn dכn dכn de sho se di bεlε fεt dכn dכn, we kכlכsכl wit di risk fכ kכdivaskyul sik. Dis sho se Survodutide nɔ jɔs de ridyus di bɔdi wet bɔt i de mek di bɔdi fat distribyushɔn bɛtɛ bay we i de ridyus di fat na di bɛlɛ, ɛn dis de mek di risk fɔ gɛt sik dɛn we gɛt fɔ du wit di bɔdi we fat pasmak.
3.3 Impruvmεnt in mεtabolik paramita dεm
Survodutide nכ de כnli rεgεl di bכdi wet bכt i gεt fayn ifekt pan mכltipכl mεtabolik paramita dεm. we i kam pan di lipid mεtabolism, insay di tritmεnt tεm, triglisεrayd (TG) dεn dכn bכku bכku wan insay כl di Survodutide grup dεm, εn vεri lכw-dεnsiti lipoprotein (VLDL) dכn dכn sכmtεm insay כl di Survodutide dכz grup dεm. LDL dכn dכn insay di 2.4 εn 3.6 mg doz grup dεm, we di tכtal kכlestכl (TC) εn nכn-HDL kכlestכl (nכn-HDL-C) dכn dכn insay di 0.6, 2.4, εn 3.6 mg grup dεm. HDL bin stil stebul ɔl di tɛm we dɛn bin de trit am. Fɔ tɔk bɔt blɔd prɛshɔn, insay rial tritmɛnt, Survodutide kin ridyus di sistolik blɔd prɛshɔn (SBP) bay 10.2 mmHg ɛn dayastolik blɔd prɛshɔn (DBP) bay 4.8 mmHg, wit di sem kayn blɔd prɛshɔn-lɔring ifɛkt dɛn we dɛn si ilɛksɛf aypatɛnshɔn bin de bifo dɛn skrin. Dɛn impɔtant tin ya we dɛn dɔn mek pan di mɛtabolik paramita dɛn de ɛp fɔ ridyus di risk fɔ gɛt di sik we dɛn kɔl kadiovaskular sik pan pipul dɛn we fat, we de sho mɔ bɔt di kɔmprɛhɛnsif advantej dɛn we Survodutide gɛt fɔ trit pipul dɛn we fat.
3.4 Mɛkanism fɔ Akshɔn
Survodutide de du in weit-lכs ifekt dεm bay we i de aktibכt GCGR εn GLP-1R. di aktibכshכn fכ GLP-1R de mek insulin sekreshכn, i de mek insulin sεnsitiviti bכku, i de sכpres di apɛtit, εn i de ridyus di it we i de it. I de delay bak fɔ ɛmti di bɛlɛ, i de mek di tɛm we di it de na di bɛlɛ lɔng ɛn i de mek di bɔdi satis mɔ. aktibכshכn fכ GCGR de tek pat pan hεpatik mεtabolik rεguleshכn bay we i de protεkt fεt כksidεshכn εn inhεbit fεt sεntez, we de ridyus fεt akyumyuleshכn na di bכdi. sכvכdutayd kin infכlכw bak di enεji mεtabolism εn di bכdi wet tru indaykt mεkanism dεm lεk fכ rεgεl di gכt maykrobayta.
4. Aplikeshɔn fɔ Survodutide insay di Tritmɛnt fɔ Fat
4.1 Klinik Risach Evidɛns
Insay wan stɔdi we dɛn du pan pasɛnt dɛn we gɛt tayp 2 dayabitis ɛn we fat, Survodutide sho bak se i gɛt gud haypoglycemic ɛn weight-loss effects. Afta 16 wiks we dɛn trit di sikman dɛn, di ɛmoglobin A1c (HbA1c) lɛvɛl dɛn we di sikman dɛn gɛt bin rili dɔŋ, wit maksimal ridyushɔn we na 1.7%, ɛn di bɔdi wet sɛf bin go dɔŋ bad bad wan, wit maksimal ridyushɔn we na 14.9%. Insay wan stɔdi we dɛn du pan pasɛnt dɛn we gɛt mɛtabolik disfɔkshɔn-asɔsiet steatohepatitis (MASH) ɛn fat, Survodutide nɔ bin jɔs impɔtant liva histɔlɔjik mak dɛn bɔt i bin mek di pasɛnt dɛn lɔs dɛn wet. Dɛn stɔdi ya kɔnfyus mɔ di ɛfifikɛshɔn fɔ Survodutide insay difrɛn pipul dɛn we gɛt kɔndishɔn dɛn we gɛt fɔ du wit fat.
4.2 Kɔmparativ Advantej Ɔva Ɔda Drug Dɛm
We yu kɔmpia am wit tradishɔnal mɛrɛsin dɛn we de mek pɔsin nɔ gɛt bɔku bɔku bɔdi, Survodutide gɛt bɔku bɛnifit dɛn. Bɔku tɛm, di tradishɔnal mɛrɛsin dɛn we dɛn kin yuz fɔ lɔs yu wet kin tɔch wan we, we kin mek dɛn nɔ ebul fɔ wok fayn ɛn dɛn kin gɛt bad bad tin dɛn fɔ du. כltu, sכvכdutayd de akt tru dual rεsεpכta agonistism, we de ridyus di bכdi wet fayn fayn wan we di sem tεm de impruv mεtabolik paramita dεm lεk bכdi glukכs, lipid lεvεl, εn blכd prεshכn, we de gi kכmprεhεnsiv prεvεnshכn εn tritmεnt fכ komplikashכn dεm we rilayt fכ fat.
we yu kכmpεr wit כda nכvel weit-lכs dכg dεm lεk semaglutide (a GLP-1 rεsεptכr agonist), insay animal εkspεriεns, כl tu di Survodutide εn semaglutide indyuz weit lכs. Bɔt, Survodutide sho mɔ yunik ifɛkt pan di it we dɛn lɛk ɛn di lipid abnɔmaliti. Semaglutid de ridyus di it we yu de it insay di fɔs stej dɛm fɔ tritmɛnt bɔt i de kam bak to di beslayn lɛvɛl leta, we Survodutide de kɔntinyu fɔ ridyus di it we yu de it we gɛt bɔku fat ɛn wata we gɛt bɔku fruktɔs fɔ 5 wik tritmɛnt tɛm. fכ di lipid profayl dεm, Semaglutid fכs fכ ridyus di tכtal kכlestכl bay we i de lכs HDL-kכlestכl, we Survodutide de sho se kכlestכl rεdukshכn akraos כl di lipoprotein kכmכpכnεnt dεm, inklud LDL-kכlestכl. dis sho se Survodutide kin gi supεriכr ifekt dεm fכ rεgεl di it intake εn lipid profayl dεm.
5. Fɔ dɔn
Survodutide, as nכvel dual agonist fכ GCGR/GLP-1R, de sho se i gεt sכmtin we i de du fכ trit fכ fat. I nɔ jɔs de ridyus di bɔdi wet fayn fayn wan ɛn i de mek di bɔdi fat distribyushɔn bɛtɛ bɔt i de rigul bɔku mɛtabolik paramita dɛn lɛk blɔd glukɔs, blɔd lipid, ɛn blɔd prɛshɔn, we de gi bɔku bɛnifit to di wan dɛn we fat.
Sos dɛn we dɛn pul
[1] Yusif A, Hasan E, Mudarres M. F., ɛn ɔda pipul dɛn. Survodutide, wan nyu horizon in di tritmεnt fכ fat εn Tayp 2 dayabεtis mεllitus: Wan narativ rivyu[J]. Yemen Jɔnal fɔ Mɛdisin, 2024,3:97-101.DOI:10.18231/j.yjom.2024.005.
[2] Le Roux CW, Steen O, Lukas K. J., ɛn ɔda pipul dɛn. 6926 Sabgrup Analysis bay Jεnda εn Bכdi Mas Indeks (BMI) in Pipul dεm we De Liv wit Ovaweyt/Obesiti in di Survodutide, wan Glucagon/GLP-1 Risεptor Dual Agonist, Faz II Trayal[J]. J ɔ rnal ov di Ɛndokrin Sɔsayti, 2024,8(Saplimɛnt_1):bvae133-bvae163.DOI:10.1210/jendso/bvae163.033.
[3] Sanyal A. J., Bedossa P., Fraessdorf M, ɛn ɔda pipul dɛn. A Faz 2 Randomized Trial of Survodutide in MASH ɛn Fibrosis.[J]. Di Nyu Ingland Jɔnal fɔ Mɛdisin, 2024.
[4] Briand F, Ɔgɔstin R, Blɛymɛl K, ɛn ɔda pipul dɛn. 7279 Survodutide εn Semaglutid כl tu de indyuz weit lכs bכt sho difrεnt ifekt dεm pan fכd prεfrεns εn dislipidemia in di fri chכys dayεt-indyuz כbis hamsta mכdel[J]. J ɔ rnal ov di Ɛndokrin Sɔsayti, 2024,8(Saplimɛnt_1):bvae134-bvae163.DOI:10.1210/jendso/bvae163.034.
[5] Her MBU, Rosenstɔk J, Hoefler J, ɛn ɔda pipul dɛn. Doz–rεspכns ifekt pan HbA1c εn bכdi wεyt rεdukshכn fכ survodutide, we na dual glucagon/GLP-1 rεsεptכr agonist, kכmpεr wit plasεbo εn opin-lεbul semaglutide in pipul dεm wit tayp 2 dayabεtis: wan randomizεd klinik trial[J]. Diabɛtɛlɔjia, 2023,67:470-482.
Prodak we de fɔ yuz fɔ risach nɔmɔ:
